Merck KGaA (MRK) Given a €105.00 Price Target at Sanford C. Bernstein

Merck KGaA (FRA:MRK) received a €105.00 ($122.09) price objective from research analysts at Sanford C. Bernstein in a report issued on Thursday, February 28th. The firm presently has a “buy” rating on the healthcare company’s stock. Sanford C. Bernstein’s price target points to a potential upside of 5.97% from the company’s previous close.

Other equities analysts have also issued research reports about the company. Kepler Capital Markets set a €108.00 ($125.58) price target on Merck KGaA and gave the company a “buy” rating in a research report on Thursday, November 15th. Credit Suisse Group set a €110.00 ($127.91) price target on Merck KGaA and gave the company a “buy” rating in a research report on Thursday, November 15th. Commerzbank set a €100.00 ($116.28) price target on Merck KGaA and gave the company a “buy” rating in a research report on Wednesday, November 14th. Berenberg Bank set a €102.00 ($118.60) price target on Merck KGaA and gave the company a “buy” rating in a research report on Friday, November 23rd. Finally, Oddo Bhf set a €100.00 ($116.28) price objective on Merck KGaA and gave the stock a “neutral” rating in a research report on Wednesday, November 14th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of €100.00 ($116.28).

Shares of FRA:MRK traded up €0.38 ($0.44) during midday trading on Thursday, reaching €99.08 ($115.21). The company had a trading volume of 536,385 shares. Merck KGaA has a 1-year low of €76.60 ($89.07) and a 1-year high of €115.00 ($133.72).

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, and colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

See Also: Dividend Aristocrat Index

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.